Vaccinex Inc. is a clinical-stage immunotherapy company focused on developing targeted biotherapeutics to treat unmet medical needs, including cancer and neurodegenerative diseases. The company is currently conducting clinical trials on Non-Small Cell Lung Cancer and Huntington’s disease. Vaccinex is utilizing its proprietary drug discovery platform, ActivMAb®, to expand its pipeline and develop high-value antibodies to multi-pass membrane receptors. Based in Rochester, New York, the company is also seeking strategic collaborations to accelerate its drug development efforts.